Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2025)

Historic Change in Receivables for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q3 2025 value amounting to $14.0 million.

  • ARS Pharmaceuticals' Change in Receivables rose 171203.1% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 452923.67%. This contributed to the annual value of $8.2 million for FY2024, which is N/A changed from last year.
  • ARS Pharmaceuticals' Change in Receivables amounted to $14.0 million in Q3 2025, which was up 171203.1% from $13.2 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Change in Receivables high stood at $14.0 million for Q3 2025, and its period low was $773000.0 during Q3 2024.